Immunoassays for lamotrigine
AssigneeSeradyn, Inc.
InventorsAnlong Ouyang, Lili Arabshahi, Mark Roberts, Melissa Wall
Life of this patent
Estimating the term…
Abstract
Generally, the present invention relates to lamotrigine analogs that have substituents at the triazine 3-position and on the benzene 4-position and 5-position. The lamotrigine analogs can include immunogenic moieties that can be used to prepare anti-lamotrigine antibodies, or antigenic moieties that can be used in immunodiagnostic assays for lamotrigine. Also, the lamotrigine analog can include tracer moieties for detecting the presence or amount of the analog during an immunodiagnostic assay. Additionally, the lamotrigine analogs can be used in immunodiagnostic assays to compete with lamotrigine for binding with anti-lamotrigine antibodies.
Claims18
A kit for use in an immunodiagnostic assay for detecting the presence of lamotrigine in a sample, the kit comprising:
- a lamotrigine analog having a chemical structure of one of Formula 1 or Formula 2;
- L is NH;
- W is selected from the group consisting of CO(CH2)2CONHCH2, CO(CH2)2CONH(CH2)2, or CONH(CH2)3;
- X is a covalent bond between W and Y or any one of NHCH2, NH(CH2)2, NH(CH2)3, NH(CH2)4, NH(CH2)5, NH(CH2)6, NHCO(CH2)2, or NHCO(CH2)6;
- Y is selected from the group consisting of COOH, COO—NHS, COO-tertbutyl, NH2, or OH;
- or
- Y is Y1-Z, wherein Y1 is selected from the group consisting of COO, CO, O, CONH, NHCO, or NH and Z is an operative group;
- and
- an anti-lamotrigine antibody having at least one binding domain, the antibody having a portion capable of binding lamotrigine and/or a lamotrigine analog, wherein an interaction between the antibody and the lamotrigine analog is at least 50% of at least one of affinity, specificity, or avidity of the antibody for lamotrigine.
A method of performing an immunodiagnostic assay for detecting the presence of lamotrigine in a sample obtained from a subject previously administered lamotrigine, the method comprising:
- combining an anti-lamotrigine antibody and a lamotrigine analog with a sample to form a first composition, said antibody being capable of binding lamotrigine and the lamotrigine analog, wherein an interaction between the antibody and the lamotrigine analog is at least 50% of at least one of affinity, specificity, or avidity of the antibody for lamotrigine, and wherein the lamotrigine analog has a chemical structure of one of Formula 1 or Formula 2;
- L is NH;
- W is selected from the group consisting of CO(CH2)2CONHCH2, CO(CH2)2CONH(CH2)2, or CONH(CH2)3;
- X is a covalent bond between W and Y or any one of NHCH2, NH(CH2)2, NH(CH2)3, NH(CH2)4, NH(CH2)5, NH(CH2)6 NHCO(CH2)2, NHCO(CH2)6;
- Y is selected from the group consisting of COOH, COO—NHS, COO-tertbutyl, NH2, or OH;
- or
- Y is Y1-Z, wherein Y1 is selected from the group consisting of COO, CO, O, CONH, NHCO, or NH and Z is an operative group;
- allowing any free lamotrigine from the sample and the lamotrigine analog to compete for binding with the antibody;
- and
- detecting binding between the lamotrigine analog and the antibody.
Dependencies are inferred from the claim text.